Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Related posts

• Latest breakthrough in Type 1 diabetes treatment: Chinese medical team enables 24 patients to discontinue insulin use

  August 21, 2025 GlobeNewswire 0

  Latest breakthrough in Type 1 diabetes treatment: Chinese medical team enables 24 patients to discontinue insulin use

  Source: Medical

  Medical 

• Advanced Ceramics and Nanoceramics Lead the Way in a Market Positioned for Long-Term Growth

  August 13, 2025 GlobeNewswire 0

  Advanced Ceramics and Nanoceramics Lead the Way in a Market Positioned for Long-Term Growth

  Source: Medical

  Medical 

• Smart Medical Devices Market to Grow at 17.1% CAGR Through 2030

  August 13, 2025 GlobeNewswire 0

  Smart Medical Devices Market to Grow at 17.1% CAGR Through 2030

  Source: Medical

  Medical